The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.
TRAIL and targeting cancer cells: between promises and obstacles
Corresponding Author(s) : Y Limami
limami@hotmail.com
Cellular and Molecular Biology,
Vol. 61 No. 6: Advances in molecular oncology: Closer analysis of recent breakthroughs
Abstract
Targeting cancer cells is one of the challenges of current treatment strategies. TRAIL represents a promising therapeutic approach and over the past decades there was an increased interest in targeting TRAIL signaling to treat cancer. Indeed, TRAIL can specifically target cancer cells and exhibits very low cytotoxicity towards normal cells. However, rapidly accumulating experimental evidence has started to shed light on multiple factors which induce resistance against TRAIL in cancer cells. This resistance consists of various mechanisms including downregulation of death receptors and caspase-8 and overexpression of decoy receptors as well as antiapoptotic factors such as members of Bcl-2 family. Even if several studies focused on elucidating those resistance mechanisms, there still remain gray areas that need to be fully elucidated. Thus, therapeutic approaches could consist of targeting both resistance signaling pathways and TRAIL signaling to enhance TRAIL therapy efficiency.
Keywords
Cancer
TRAIL
Targeted therapy
Apoptosis
TRAIL resistance
Clinical Trials.
Limami, Y., Pinon, A., Riaz, A., & Simon, A. (2015). TRAIL and targeting cancer cells: between promises and obstacles. Cellular and Molecular Biology, 61(6), 33–38. Retrieved from https://mail.cellmolbiol.org/index.php/CMB/article/view/721
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX